Advancements in platform and technology developments for bispecific and multispecific antibodies are leading to a profusion of new constructs that promise better functionality and efficacy than ever before. These efforts, combined with the careful analysis and assessment of preclinical and clinical results, will help to advance the field forward and propel novel modalities to FDA approval, and ultimately, to patients. However, additional improvements in manufacturability and safety need to be made to ensure their dominance in the marketplace. Industry leaders will be discussing translational approaches and optimisation of candidates to advance this growing repertoire of successful multispecific antibody therapeutics through clinical development to the market.
Scientific Advisory Board:
Paul Parren
, PhD, CSO, Gyes; Professor, Molecular Immunology, Leiden University Medical Center
Tariq Ghayur
, PhD, Tariq Ghayur Consulting, LLC and Entrepreneur in Residence, FairJourney Biologics